ArriVent BioPharma, Inc.
AVBP • NASDAQ
ArriVent BioPharma, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Zhengbin Yao, with a market cap of $947.2M.
Market Cap$947.2M
Employees40.0
CEOZhengbin Yao
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 11, 2026 · in a monthQ1 2026
Financials
AVB
ArriVent BioPharma, Inc. FAQ
Common questions about ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. is scheduled to report earnings for Q1 2026 on May 11, 2026.
ArriVent BioPharma, Inc. has approximately 40 employees.